New class of haemophilia A treatment

Clinical

New class of haemophilia A treatment

In Clinical

The European Commission recently approved emicizumab (Hemlibra) to prevent bleeding episodes in people with severe haemophilia A without factor VIII inhibitors.

Roche Products and Chugai Pharma say that emicizumab is the “first new class of medicine to treat these haemophilia A patients in nearly 20 years”.

Emicizumab is already approved for haemophilia A with inhibitors to factor VIII. The new approval was based on the HAVEN 3 study, which showed that emicizumab once weekly or once every two weeks reduced treated bleeds by 96 and 97 per cent (annualised treated bleed rate [ABR] 1.5 and 1.3) respectively compared to factor VIII treatment given on-demand (ABR 38.2).

The most serious adverse reactions in the clinical trials were thrombotic microangiopathy and thrombotic events.

Record my learning outcomes

Clinical

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share: